bpc 157 nasal spray efficacy BPC-157/TB-500: Nasal Application vs. Other Methods Nasal Spray - CellGenic |

This content is for educational purposes only and does not constitute medical advice

It has been studied in clinical trials involving over 2,000 individuals, is approved for use in over 30 countries (primarily for hepatitis and cancer immunotherapy), and has specific published research in autoimmune populations including RA, SLE, and MS patients

References For general education only not medical advice or a treatment recommendation

The standard NHS regimen for treating deficiency involves loading doses followed by maintenance therapy, with frequency determined by the underlying cause and severity of deficiency

(PubMed) Molloy AM

Safety Warning Consult a healthcare professional before use